JPY 1,344.00
+11.00 (+0.83%)
JPY · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 3402.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 2 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of TRK-950 in Patients With Advanced Solid TumorsNCT05423262Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: TRK-950, TRK-950, TRK-950, TRK-950 · Drug: Nivolumab | Solid Tumor, Melanoma | 49 | Dec 2027 | ≤ 498 d | 2026-04-13 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | Jun 2026 | — | 2026-06-23 |
| A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerNCT06038578Progression free Survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: TRK-950 · Drug: Ramucirumab, Paclitaxel | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 146 | 2026-06-30 | — | 2026-06-23 |
| Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)NCT04804943Ventilator Free Days (VFD, Days alive and ventilator-free)Randomized · Open-label · Treatment | Not applicable | Unknown status | Device: NOA-001 | Acute Respiratory Distress Syndrome | 45 | 2025-06-30 | — | 2024-07-09 |
| Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary FibrosisNCT03727802results2023-10-23Incidence and Severity of Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: TRK-250, Placebo | Idiopathic Pulmonary Fibrosis | 34 | 2022-04-01actual | — | 2023-10-23 |
| A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)NCT04282590Incidence of adverse events as assessed by CTCAE v5.0Randomized · Triple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: due to COVID-19 pandemic | Drug: TRK-750/Placebo, Placebo/TRK-750 | Chemotherapy-induced Peripheral Neuropathy | 0 | Dec 2021 | — | 2022-03-15 |
| A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid TumorsNCT02990481Adverse eventNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: TRK-950, TRK-950, TRK-950 | Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma | 38 | 2019-09-16actual | — | 2025-04-16 |
| Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750NCT03346330Incidence of treatment-emergent adverse events as assessed by CTCAE v4.03Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: TRK-750, Placebo | Healthy, Peripheral Neuropathic Pain | 105 | 2018-08-31actual | — | 2018-12-19 |
| Efficacy and Safety of TRK-700 in Patient With Post-Herpetic NeuralgiaNCT02701374Change in average Numerical Rating Scale (NRS)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TRK-700, Placebo | Post-Herpetic Neuralgia | 184 | Jul 2017actual | — | 2017-10-25 |
| TRK-820 Study in Subjects on Hemodialysis With or Without Uremic PruritusNCT03002233Pharmacokinetic parameters: area under the time curve from time zero to 24 hours postdose(AUC0-24h)Open-label · Treatment | Phase 1 | Completed | Drug: TRK-820 | Uremic Pruritus | 23 | Jul 2017actual | — | 2017-07-21 |
| TRK-700 Drug-Drug Interaction Study With Digoxin and MidazolamNCT03043248Area under the plasma drug concentration - time curve from administration to the last available concentration measurement of Digoxin and Midazolam(AUClast)Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: TRK-700, Digoxin, Midazolam | Healthy | 48 | 2017-05-13actual | — | 2017-10-25 |
| TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)NCT01090037Renal composite endpoints [Time to first occurrence of one of the following events:]Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: TRK-100STP high dose, TRK-100STP low dose, Placebo | Chronic Renal Failure, Glomerular Disease, Nephrosclerosis | 892 | Aug 2014actual | — | 2015-02-04 |
| Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving HemodialysisNCT01660243results2022-02-09Change From Baseline in Worst-itching 11-point Numerical Rating Scale (NRS)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: This study has been terminated because of insufficient patient recruitment. | Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg, Nalfurafine hydrochloride(MT-9938) 5μg, Nalfurafine hydrochloride(MT-9938) 10μg, Placebo | Uremic Pruritus | 45 | Mar 2014actual | — | 2022-02-09 |
| A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal ImpairmentNCT01443429Composite of pharmacokinetic parameters of TRK-100STP such as maximum observed concentration (Cmax,pg/mL), area under the plasma concentration-time curve (AUC,pg·hr/mL), time at maximum concentration (Tmax,hr) and mean residence time (MRT,hr)Non-randomized · Open-label | Phase 1 | Completed | Drug: beraprost sodium(BPS) | Renal Impairment | 24 | Feb 2014actual | — | 2014-03-04 |
| Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -NCT00638495Change in VAS value (based on morning or evening scores, whichever larger, during the treatment period [4th week])Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Nalfurafine Hydrochloride (TRK-820), Placebo | Pruritus With Chronic Liver Disease | 120 | Dec 2009actual | — | 2010-02-01 |
| TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)NCT02480751Difference between the run-in and treatment periods in the slope of the regression line of 1/SCr versus timeRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Beraprost, Placebo | Renal Insufficiency, Chronic | 113 | May 2008actual | — | 2015-06-29 |
| A Study of TRK-170 for the Treatment of Crohn's DiseaseNCT01345799Crohn's Disease Activity IndexRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TRK-170, Placebo | Crohn's Disease | 123 | — | — | 2014-06-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19